LONDON, March 18 - Merck & Co is donating an experimental anti-malarial medicine to a not-for-profit research organisation in the latest example of drugmakers stepping up efforts to address health issues in poor countries.
Companies have come under increasing pressure in recent years to do such deals in order to improve access to modern drugs in the developing world at affordable prices.
Last month, GlaxoSmithKline's chief executive urged the creation of a voluntary patent pool to spark development of new treatments for neglected diseases, including malaria.
Merck said on Wednesday it had granted the Medicines for Malaria Venture (MMV) an exclusive, royalty-free licence to develop a compound discovered by its scientists. Merck will have the option to partner the drug after completion of mid-stage tests.
If you believe an article violates your rights or the rights of others, please contact us.